OOIR: Observatory of International Research

Papers

(The TQCC of Current Opinion in Rheumatology is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Editorial introduction	244
Giant cell arteritis: update on pathogenesis and clinical implications	67
Current approach to muscle imaging in myositis	62
What's next in psoriatic arthritis therapy? A look at the pipeline	53
Epidemiology and outcomes of rheumatoid arthritis	50
Current views on lupus in children	49
Selective immunoglobulin E deficiency: an overlooked hypogammaglobulinemia and its association with rheumatoid arthritis	49
Urticarial vasculitis	47
Update on antineutrophil cytoplasmic autoantibody vasculitis in children	39
Polymyalgia rheumatica and giant cell arteritis: diagnosis and management	35
Editorial introductions	35
Osteoporosis epidemiology using international cohorts	34
Patient-reported outcomes in systemic sclerosis: insights into quality of life and disease burden	34
Axial spondyloarthritis guidelines – aiming for maximum impact	30
Juvenile Behçet syndrome: a contemporary view and differential diagnosis in pediatric practice	25
A comprehensive review of systemic sclerosis–primary biliary cholangitis overlap: emerging evidence for a distinct clinical subtype	24
The gut microbiota in spondyloarthritis: an update	23
Comorbidities in idiopathic inflammatory myopathies: population-based evidence on risk subgroups and implications for delivery of care	22
Rheumatoid arthritis – the challenge of heterogeneity	21
Composite measures to assess disease damage, disease severity and treatment response in systemic sclerosis clinical trials	21
Recent advances in the use of machine learning and artificial intelligence to improve diagnosis, predict flares, and enrich clinical trials in lupus	20
Editorial introductions	19
Updates on translational and clinical research in systemic sclerosis	19
VEXAS syndrome: an adult-onset autoinflammatory disorder with underlying somatic mutation	18
Editorial introductions	18

Editorial introductions	17
The role of PET/CT in disease activity assessment in patients with large vessel vasculitis	17
Editorial introduction	16
Insights into the pathogenic role of neutrophils in systemic lupus erythematosus	16
Pathogenesis of skin damage in lupus: recent advances and future directions	16
Management of cutaneous manifestations of systemic sclerosis: current approaches and emerging therapies	15
The role of neutrophil extracellular traps in inflammatory rheumatic diseases	15
Pathogenesis of vasculopathy in systemic sclerosis and its contribution to fibrosis	14
Defining and managing flares in axial spondyloarthritis	14
Health inequities in the rheumatic diseases of childhood	14
Understanding the gastrointestinal microbiome in systemic sclerosis: methodological advancements and emerging research	14
Epidemiology of myositis	13
Chimeric antigen receptor T-cell therapy in rheumatology: B-cell depletion 2.0	13
Nonsteroidal anti-inflammatory drugs and cardiovascular disease risk in spondyloarthritis-spectrum diseases	13
Emerging synovial cell states in rheumatoid arthritis as potential therapeutic targets	13
How common is vasculitis: what do population-based data tell us?	13
AI am the future: artificial intelligence in pediatric rheumatology	12
Is it time to move on from pelvic radiography as the first-line imaging modality for suspected sacroiliitis?	12
New developments related to lung complications in pediatric rheumatic disease	12
Biomarker discovery in psoriatic disease	12
Editorial introductions	12
Diagnosis and management of primary heart involvement in systemic sclerosis	11
Advances in the diagnosis and treatment of Sjögren disease	11
Epidemiology of osteoarthritis: literature update 2022–2023	11
Environmental and occupational contributors to autoimmune, inflammatory, and musculoskeletal rheumatic disease: a review of emerging evidence and clinical implications	11
Exploring challenges in the management and treatment of inclusion body myositis	11
Management of postinfectious inflammatory arthritis	11
Editorial introduction	11
Investigating gout flares: beyond a definition	11
Emerging biologic therapies for systemic lupus erythematosus	11
Gastrointestinal involvement in systemic sclerosis: pathogenesis, assessment and treatment	10
Animal models in systemic sclerosis: an update	10
Heart involvement in systemic sclerosis: emerging concepts	10
Decoding vascular dysfunction in systemic sclerosis: from endothelial damage to clinical implications	10
Update on streptococcal-associated rheumatic disease	10
Eosinophilic granulomatosis with polyangiitis: recent therapeutic advances	10
Gastrointestinal disease in systemic sclerosis: the neglected organ system?	10
Advances in the diagnosis of multiorgan involvement in systemic sclerosis: a focus on MRI	10
Vasculitis and the NLRP3 inflammasome	10
What have we learned about systemic sclerosis from the EUSTAR database?	9
Biomarkers in juvenile idiopathic arthritis: towards precision diagnosis and personalized therapy?	9
Pediatric antiphospholipid syndrome: expanding our understanding of antiphospholipid syndrome in children	9
Revisiting the CD40-CD40L axis: from mechanistic insight to therapeutic renewal in autoimmune disease	9
Emerging cellular and immunotherapies for systemic sclerosis: from mesenchymal stromal cells to CAR-T cells and vaccine-based approaches	9
Treatment of systemic vasculitis	9
Editorial introduction	9
The contribution of endothelial cells to tissue fibrosis	9
Recent developments in the synovial fibroblast pathobiology field in rheumatoid arthritis	9
Biologic disease-modifying antirheumatic drugs to treat multisystem inflammatory syndrome in children	9
Current management of giant cell arteritis and its complications	9

Pregnancies in women with antineutrophil cytoplasmatic antibody associated vasculitis